Pharsight Corp

Pharsight — Q4 2007 Earnings Presentation

45 slides from Pharsight's earnings presentation, May 14, 2007

  1. Slide 1: Pharsight Corporation Investor Presentation

    Slide 1: Pharsight Corporation Investor Presentation

    Exhibit 99.1 Pharsight Corporation Investor Presentation 4th Quarter Fiscal 2007 Update March 31, 2007 Shawn O’Connor President, Chairman and CEO Will Frederick CFO Confidential © Pharsight Corporation

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements, including statements regarding our financial model, growth opportunities and strategic investments, our market position, the demand and market opportunity for our products and services, financial and product performanc

  3. Slide 3: Overview

    Slide 3: Overview

    Overview • Profile – Founded in 1995 with IPO in August 2000 – Offices in Mountain View, CA (HQ) and Cary, NC (R&D) – Global headcount approximately 90 – Stock traded OTCBB: PHST • Key Industry Considerations – Large Pharmaceutical and biotech marketplace – Outsourcing of development activities esca

  4. Slide 4: Pharsight Capabilities Supporting Efficient Drug Development

    Slide 4: Pharsight Capabilities Supporting Efficient Drug Development

    Pharsight Capabilities Supporting Efficient Drug Development Strategic Consulting Reporting and Software Products Services Analysis Services Improve productivity and Quantify your decision- Outsource reporting and compliance making analysis Enterprise and desktop products Consulting expertise in mod

  5. Slide 5: FDA Influence Driving Market Adoption

    Slide 5: FDA Influence Driving Market Adoption

    FDA Influence Driving Market Adoption FDA and Pharsight sign CRADA - June 2006 • Pharsight will make available a comprehensive suite of software tools, including: Pharsight ® Knowledgebase Server™ (PKS™), PKS Validation Suite™, WinNonlin ® Validation Suite™, Trial Simulator™-and Drug Model Explorer™

  6. Slide 6: Market Opportunity: Drug Development Cost and Timeline

    Slide 6: Market Opportunity: Drug Development Cost and Timeline

    Market Opportunity Drug Development Cost and Timeline Research Clinical Development $25 Billion 1 $48 Billion 1 • High throughput screening • Long, risky and complex process • Combinatorial chemistry • Of 5,000 screened • Genomics compounds: 250 enter preclinical testing, 5 • Rational drug design en

  7. Slide 7: Market Opportunity: Software Product Diversification

    Slide 7: Market Opportunity: Software Product Diversification

    Market Opportunity Software Product Diversification • Customers expanding their use of the Pharsight family of products can create $100K to $500K+ in initial revenue and increases of 15x in ongoing maintenance revenue $90K+ maint. $90K After Diversification Before WNL Enterprise Diversification WNL

  8. Slide 8: Current Customers Includes All Top 50 Pharma Companies

    Slide 8: Current Customers Includes All Top 50 Pharma Companies

    Current Customers Includes All Top 50 Pharma Companies Copyright © 2007 Pharsight Corporation. All rights reserved. 8

  9. Slide 9: Software Products

    Slide 9: Software Products

    Software Products Confidential © Pharsight Corporation

  10. Slide 10: Software Products Overview

    Slide 10: Software Products Overview

    Software Products Overview • Analytics – WinNonlin ® – WinNonMix ® – Trial Simulator™ – IVIVC Toolkit™ for WinNonlin • Data Management & Compliance – Pharsight ® Knowledgebase Server™ – PKS Reporter – WinNonlin AutoPilot™ • Validation – WinNonlin Validation Suite™ – PKS Validation Suite™ • Model Vis

  11. Slide 11: Software Products Market Acceptance

    Slide 11: Software Products Market Acceptance

    Software Products 1 Market Acceptance • Over 1,250 active software customers 2 • All Top 50 Pharma license at least one of our software products • Our software applications are licensed for use on more than 6,700 desktops in industry and academia 2 TM • 13 of the Top 50 Pharma are PKS customers – 19

  12. Slide 12: Software Products Return on Investment Example: Pfizer

    Slide 12: Software Products Return on Investment Example: Pfizer

    Software Products Return on Investment Example Pfizer “Within 2 years of (implementing Pharsight’s WinNonlin automation and other measures) the two people conducting the routine pharmacokinetic studies had completed 45 studies in 1 year.” (previous staff of 19 for the same work) “The cycle time to i

  13. Slide 13: WinNonlin (WNL)

    Slide 13: WinNonlin (WNL)

    Software Products WinNonlin ® (“WNL™”) Industry Gold-Standard for Pharmacokinetic (“PK”), Pharmacodynamic (“PD”) Modeling, and Non Compartmental Analysis • Key Benefits – Used to simulate effects of different dosing regimens and changes in pharmacokinetic parameters required in regulatory submission

  14. Slide 14: WinNonMix (WNM)

    Slide 14: WinNonMix (WNM)

    Software Products WinNonMix ® (“WNM™”) Nonlinear Mixed Effects (Population) Analysis Software Application • Key Benefits – Extensive built-in library of PK, PD and PK-PD models – NONMEM data import wizard – Built-in report-ready graphics capability – Estimation algorithms for sparse and for rich dat

  15. Slide 15: Trial Simulator

    Slide 15: Trial Simulator

    Software Products Trial Simulator™ State-of-the-Art Clinical Trial Design and Simulation Software • Key Benefits – Minimize risk of trial design – Formalize assumptions – Quantify uncertainty – Reduce cost of clinical trials and drug development time-to-market • Potential Growth Drivers – Increase p

  16. Slide 16: IVIVC Toolkit for WinNonlin

    Slide 16: IVIVC Toolkit for WinNonlin

    Software Products IVIVC Toolkit™ for WinNonlin In vivo-in vitro correlations (IVIVC) • Key Benefits – Speed formulation development – Improve success of bioequivalence studies – Reduce expense and time needed for in vivo studies • Potential Growth Drivers – Increase interoperability with other Phars

  17. Slide 17: Pharsight Knowledgebase Server (PKS)

    Slide 17: Pharsight Knowledgebase Server (PKS)

    Software Products Pharsight ® Knowledgebase Server™ (“PKS™”) Enterprise Data Management Systems for Secure Storage and Management of PK/PD Data • Key Benefits – Dramatically improves data management and data access – Increases productivity in analysis and reporting tasks – Supports compliance with F

  18. Slide 18: WinNonlin AutoPilot

    Slide 18: WinNonlin AutoPilot

    Software Products WinNonlin AutoPilot™ Streamlining Routine Clinical PK Analyses and Reporting • Key Benefits – Capture and implement best practices and business rules within a department and across sites. – Standardize content and formatting of analyses and reports to reduce authoring/review effort

  19. Slide 19: Drug Model Explorer (DMX)

    Slide 19: Drug Model Explorer (DMX)

    Software Products Drug Model Explorer™ (“DMX ® ”) Software-Based Communication Technology, Designed to Facilitate Quantitative Decision-Making in Drug Development • Key Benefits – Facilitates more efficient collaboration within project teams to explore key drug attributes, and their respective uncer

  20. Slide 20: Strategic Consulting Services

    Slide 20: Strategic Consulting Services

    Strategic Consulting Services Confidential © Pharsight Corporation

  21. Slide 21: Strategic Consulting Services Overview

    Slide 21: Strategic Consulting Services Overview

    Strategic Consulting Services Overview • World-class experts in clinical pharmacology, PK/PD, decision analysis, and statistics • Rich mix of drug development experience from industry, academic and consulting backgrounds • Consulting engagements completed in all major therapeutic areas and indicatio

  22. Slide 22: Strategic Consulting Services Market Acceptance

    Slide 22: Strategic Consulting Services Market Acceptance

    Strategic Consulting Services Market Acceptance 1 • Over 40 active consulting clients in Fiscal 2007 2 – 19 of the Top 50 Pharma were active consulting clients – 24 new consulting clients • Over 140 projects engaged during Fiscal 2007 • Diverse Customer Workplans – Hourly engagements to annual engag

  23. Slide 23: Broad Modeling Capabilities

    Slide 23: Broad Modeling Capabilities

    Strategic Consulting Services Broad Modeling Capabilities Quantitative decision support provided on multiple projects in all phases of drug development across most major therapeutic areas and for a variety of indications Pre- Phase Phase Phase Therapeutic Area Phase I Clinical II III IV Anti-infecti

  24. Slide 24: Strategic Consulting Services Customer Value

    Slide 24: Strategic Consulting Services Customer Value

    Strategic Consulting Services Customer Value • A complete analysis of your next decision and a recommendation • Quantification of the size of the risk you take in your next decision • Information on your project of the type increasingly requested by the FDA • Access to some of the world’s leading ex

  25. Slide 25: Strategic Consulting Services Growth Drivers

    Slide 25: Strategic Consulting Services Growth Drivers

    Strategic Consulting Services Growth Drivers • Industry Factors – Increased acceptance of modeling and simulation to achieve efficient drug development decision making – FDA Critical Path Initiative advocates increased use of modeling and simulation to overcome poor development productivity – Increa

  26. Slide 26: Strategic Consulting Services Revenue Diversification

    Slide 26: Strategic Consulting Services Revenue Diversification

    Strategic Consulting Services 1 Revenue Diversification Successful Diversification Efforts with Reduced Revenue Dependency on “Top 2 Clients” FY07 FY06 38% 48% Top 2 clients Top 2 clients 52% Others Others 62% $9.3M Revenue $10.9M Revenue 1 As of March 31, 2007 Copyright © 2007 Pharsight Corporation

  27. Slide 27: Return on Investment Example: sanofi-aventis

    Slide 27: Return on Investment Example: sanofi-aventis

    Strategic Consulting Services Return on Investment Example sanofi-aventis Aventis turned to a computer model from … Pharsight. Using its own animal and human test data, Aventis was able to simulate later-stage clinical trials. Based on that simulation, “we stopped funding development of the compound

  28. Slide 28: Reporting and Analysis Services

    Slide 28: Reporting and Analysis Services

    Reporting and Analysis Services Confidential © Pharsight Corporation

  29. Slide 29: Reporting and Analysis Services Overview

    Slide 29: Reporting and Analysis Services Overview

    Reporting and Analysis Services Overview • Reporting and analysis of early- phase, regulatory- required studies • Complements software and Strategic Consulting Services • New services create deeper relationships with our clients • Leverages value of Pharsight brand in PK/PD • Provides a new source o

  30. Slide 30: Reporting and Analysis Services Growth Drivers

    Slide 30: Reporting and Analysis Services Growth Drivers

    Reporting and Analysis Services Growth Drivers • Industry Factors – Large, established market – Increased usage of outsourced capabilities – New requirements for analysis-intensive studies – Growing diversification to new delivery platforms • Internal Factors – Existing relationships with software a

  31. Slide 31: Financial Overview

    Slide 31: Financial Overview

    Financial Overview Confidential © Pharsight Corporation

  32. Slide 32: Accomplishments and Guidance

    Slide 32: Accomplishments and Guidance

    Accomplishments and Guidance FY07 Accomplishments FY08 Guidance • Revenue growth • Continued revenue growth – Y/Y revenue growth of 10% – Y/Y revenue growth of approx. 10% to th 15%, or approx. $27.5M - $29M – 4 consecutive year of revenue growth • Gross Margin • Gross Margin – 69% of revenue – Appr

  33. Slide 33: Summary Income Statements

    Slide 33: Summary Income Statements

    Summary Income Statements (in thousands) FY07 FY06 Consol. SPBU SCS Consol. SPBU SCS Revenue 25,092 14,238 10,854 22,742 13,449 9,293 Y/Y growth 10% 6% 17% 1% 11% -12% Cost of revenue 7,731 1,383 6,348 7,699 1,789 5,910 Gross profit 17,361 12,855 4,506 15,043 11,660 3,383 Gross margin 69% 90% 42% 66

  34. Slide 34: Summary Balance Sheets

    Slide 34: Summary Balance Sheets

    Summary Balance Sheets (in thousands) March 31, March 31, 2007 2006 ASSETS Cash & short term investments $ 14,665 $ 10,832 Accounts receivable, net 3,087 4,585 Total current assets 18,275 15,715 Total assets $ 19,995 $ 17,786 LIABILITIES & STOCKHOLDERS' DEFICIT A/P & accrued expenses $ 4,389 $ 3,981

  35. Slide 35: Annual Revenue by Business Unit

    Slide 35: Annual Revenue by Business Unit

    Annual Revenue by Business Unit (in thousands) $30,000 $25,000 $20,000 $15,000 $10,000 $5,000 $0 FY04 FY05 FY06 FY07 FY08 Guidance Software Products Strategic Consulting Guidance ($27.5M - $29M) Copyright © 2007 Pharsight Corporation. All rights reserved. 35

  36. Slide 36: Quarterly Revenue by Business Unit

    Slide 36: Quarterly Revenue by Business Unit

    Quarterly Revenue by Business Unit (in thousands) $8,000 $7,000 $6,000 $5,000 $4,000 $3,000 $2,000 $1,000 $0 Q4 FY06 Q1 FY07 Q2 FY07 Q3 FY07 Q4 FY07 Software Products Strategic Consulting Copyright © 2007 Pharsight Corporation. All rights reserved. 36

  37. Slide 37: Annual Gross Profit

    Slide 37: Annual Gross Profit

    Annual Gross Profit (in thousands) $17,500 $15,000 $12,500 $10,000 $7,500 $5,000 $2,500 $0 FY03 FY04 FY05 FY06 FY07 Copyright © 2007 Pharsight Corporation. All rights reserved. 37

  38. Slide 38: Annual Operating Income

    Slide 38: Annual Operating Income

    Annual Operating Income (in thousands) $5,000 $2,500 $0 -$2,500 -$5,000 -$7,500 -$10,000 -$12,500 FY03 FY04 FY05 FY06 FY07 Note: FY07 Operating Income reflects $831 for stock-based compensation expense Copyright © 2007 Pharsight Corporation. All rights reserved. 38

  39. Slide 39: Annual Operating Cash Flow

    Slide 39: Annual Operating Cash Flow

    Annual Operating Cash Flow (in thousands) $6,000 $4,000 $2,000 $0 -$2,000 -$4,000 -$6,000 -$8,000 FY03 FY04 FY05 FY06 FY07 Copyright © 2007 Pharsight Corporation. All rights reserved. 39

  40. Slide 40: Equity Overview

    Slide 40: Equity Overview

    Equity Overview 1 • Common Shares Outstanding 20 million 1 • Preferred Shares Outstanding 8 million – 1.8 million Series A and 0.2 million Series B – Conversion ratio to Common at 4:1 1 • Common Equivalent Shares (as converted) 28 million • PIPE Financing 6/02 and 9/02 = $7.5 million – 1.8 million U

  41. Slide 41: Significant Shareholders

    Slide 41: Significant Shareholders

    1 Significant Shareholders Alloy Entities 16% ownership McKesson Corp. 14% ownership Sprout Entities 9% ownership Weiss Peck & Greer 6% ownership Wellington Management Co. 4% ownership Perritt Capital Management 1% ownership Lewis Asset Management Corp. 1% ownership 1 Excludes Preferred Shares outst

  42. Slide 42: Executive Team

    Slide 42: Executive Team

    Executive Team Shawn M. O’Connor President, Chairman and Chief Executive Officer QRS, Diasonics Ultrasound, Peat Marwick Will Frederick Chief Financial Officer Versata, Clarent, ACT Networks, Disney Daniel Weiner, PhD Chief Technology Officer IVAX, Merrell Dow, Syntex, Quintiles James Hayden SVP Glo

  43. Slide 43: Summary

    Slide 43: Summary

    Summary • Current pharmaceutical market trends look favorable… • Increasing mindshare for quantitative-based modeling and simulation… • FDA's call for more modeling and simulation in the Critical Path Initiative… • Financially stable and leveragable business model… All support our drive towards expa

  44. Slide 44: Proprietary Notice

    Slide 44: Proprietary Notice

    Proprietary Notice All contents Copyright ©2007 Pharsight Corporation. All rights reserved. The copyright for this document is owned by Pharsight Corporation. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, for

  45. Slide 45: Pharsight

    Slide 45: Pharsight

    Pharsight Pharsight

Source: SEC EDGAR · 8-K filed May 14, 2007

More decks from Pharsight Corp